

Sangamo Therapeutics Logo

Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences

May 15, 2019

Hemophilia A SB-525 gene therapy clinical data accepted for oral presentation at ISTH

BRISBANE, Calif., May 15, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced participation in the following scientific, medical, and investor conferences:



Upcoming Medical & Scientific Conferences

- **2019 World Advanced Therapies and Regenerative Medicine Congress**
"Gene Editing for Therapeutic Applications"
Presentation Date: Friday, May 17th at 3:40 a.m. Eastern Time
Location: London, United Kingdom
- **Treg Directed Therapies Summit**
"Engineering CAR Regulatory T Cells (CAR-Tregs) for Autoimmunity, Inflammation & Transplantation"
Presentation Date: Wednesday, May 22nd at 9:30 a.m. Eastern Time
Location: Boston, MA
- **Update on Fabry Disease Meeting**
"Liver targeted AAV gene therapy vectors results in high levels of enzyme activity and effective substrate reduction in a mouse model of Fabry disease"
Presentation Date: Sunday, May 26th at 10 a.m. Eastern Time
Location: Prague, Czech Republic
- **International Society on Thrombosis and Haemostasis (ISTH) Congress**
"Initial results of the Alta study, a phase 1/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult subjects with severe hemophilia A"
Presentation Date: Saturday, July 6th at 1:00 p.m. Australian Eastern Standard Time (July 5th at 11 p.m. Eastern Time)
Location: Melbourne, Australia

Upcoming Investor Conference

- **Jefferies 2019 Healthcare Conference**
Presentation Date: Thursday, June 6th, at 1:30 p.m. Eastern Time
Location: New York, NY

Members of the Sangamo management team will present a corporate overview at the Jefferies 2019 Healthcare Conference. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under [Events and Presentations](#). The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, *ex vivo* gene-edited cell therapy, *in vivo* genome editing, and gene regulation. For more information about Sangamo, visit www.sangamo.com.

View original content to download multimedia: <http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-presentations-at-upcoming-scientific-medical-and-investor-conferences-300851021.html>

SOURCE Sangamo Therapeutics, Inc.

Investor Relations - United States: McDavid Stilwell, 510-970-6000, x219, mstilwell@sangamo.com; Media Inquiries - United States: Aron Feingold, 510-970-6000, x421, afeingold@sangamo.com; Investor Relations and Media Inquiries - European Union: Caroline Courme, 33 4 97 21 27 27, ccourme@sangamo.com